Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Septerna, Inc. - Common Stock
(NQ:
SEPN
)
26.51
+0.21 (+0.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
366,751
Open
26.21
Bid (Size)
25.80 (500)
Ask (Size)
28.00 (100)
Prev. Close
26.30
Today's Range
25.79 - 27.16
52wk Range
8.860 - 32.63
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at Bank of America Securities Health Care Conference
May 05, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Performance
YTD
-5.3%
-5.3%
1 Month
-1.3%
-1.3%
3 Month
-12.5%
-12.5%
6 Month
+22.5%
+22.5%
1 Year
+165.9%
+165.9%
More News
Read More
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
April 13, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
March 09, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
March 01, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
February 10, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
January 08, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in 8th Annual Evercore Healthcare Conference
November 25, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
November 10, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in Upcoming Investor Conferences
November 03, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
↗
October 15, 2025
Via
MarketBeat
Topics
World Trade
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
September 29, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in Upcoming Investor Conferences
August 27, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
August 21, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
August 11, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
↗
June 23, 2025
Via
Benzinga
This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
June 23, 2025
Via
Benzinga
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
June 23, 2025
Via
Benzinga
The Analyst Verdict: Septerna In The Eyes Of 4 Experts
↗
June 23, 2025
Via
Benzinga
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
↗
May 29, 2025
Via
Investor's Business Daily
Septerna to Present at Jefferies Global Healthcare Conference
May 29, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Analysts Think These Stocks Could More Than Double in Value
May 23, 2025
Via
MarketBeat
Topics
World Trade
Frequently Asked Questions
Is Septerna, Inc. - Common Stock publicly traded?
Yes, Septerna, Inc. - Common Stock is publicly traded.
What exchange does Septerna, Inc. - Common Stock trade on?
Septerna, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Septerna, Inc. - Common Stock?
The ticker symbol for Septerna, Inc. - Common Stock is SEPN on the Nasdaq Stock Market
What is the current price of Septerna, Inc. - Common Stock?
The current price of Septerna, Inc. - Common Stock is 26.51
When was Septerna, Inc. - Common Stock last traded?
The last trade of Septerna, Inc. - Common Stock was at 05/19/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
